Jeffrey Weitz
Jeffrey Weitz
Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University
Verified email at
Cited by
Cited by
Edoxaban versus warfarin in patients with atrial fibrillation
RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ...
New England Journal of Medicine 369 (22), 2093-2104, 2013
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
CT Ruff, RP Giugliano, E Braunwald, EB Hoffman, N Deenadayalu, ...
The Lancet 383 (9921), 955-962, 2014
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review
B Bikdeli, MV Madhavan, D Jimenez, T Chuich, I Dreyfus, E Driggin, ...
Journal of the American college of cardiology 75 (23), 2950-2973, 2020
Oral apixaban for the treatment of acute venous thromboembolism
G Agnelli, HR Buller, A Cohen, M Curto, AS Gallus, M Johnson, ...
New England Journal of Medicine 369 (9), 799-808, 2013
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer
PS Wells, DR Anderson, M Rodger, JS Ginsberg, C Kearon, M Gent, ...
Thrombosis and haemostasis 83 (03), 416-420, 2000
Low-molecular-weight heparins
JI Weitz
New England Journal of Medicine 337 (10), 688-698, 1997
Idarucizumab for dabigatran reversal
CV Pollack Jr, PA Reilly, J Eikelboom, S Glund, P Verhamme, ...
New England Journal of Medicine 373 (6), 511-520, 2015
Hematology: basic principles and practice
R Hoffman, EJ Benz Jr, LE Silberstein, H Heslop, J Anastasi, J Weitz
Elsevier Health Sciences, 2013
Apixaban for extended treatment of venous thromboembolism
G Agnelli, HR Buller, A Cohen, M Curto, AS Gallus, M Johnson, A Porcari, ...
New England Journal of Medicine 368 (8), 699-708, 2013
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
JW Eikelboom, J Hirsh, JI Weitz, M Johnston, Q Yi, S Yusuf
Circulation 105 (14), 1650-1655, 2002
Edoxaban for the treatment of cancer-associated venous thromboembolism
GE Raskob, N Van Es, P Verhamme, M Carrier, M Di Nisio, D Garcia, ...
New England Journal of Medicine 378 (7), 615-624, 2018
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
M Levine, M Gent, J Hirsh, J Leclerc, D Anderson, J Weitz, J Ginsberg, ...
New England Journal of Medicine 334 (11), 677-681, 1996
Thrombosis: a major contributor to global disease burden
GE Raskob, P Angchaisuksiri, AN Blanco, H Buller, A Gallus, BJ Hunt, ...
Arteriosclerosis, thrombosis, and vascular biology 34 (11), 2363-2371, 2014
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
C Kearon, M Gent, J Hirsh, J Weitz, MJ Kovacs, DR Anderson, AG Turpie, ...
New England Journal of Medicine 340 (12), 901-907, 1999
Use of a clinical model for safe management of patients with suspected pulmonary embolism
PS Wells, JS Ginsberg, DR Anderson, C Kearon, M Gent, AG Turpie, ...
Annals of internal medicine 129 (12), 997-1005, 1998
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
JI Weitz, M Hudoba, D Massel, J Maraganore, J Hirsh
The Journal of clinical investigation 86 (2), 385-391, 1990
Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review
JI Weitz, J Byrne, GP Clagett, ME Farkouh, JM Porter, DL Sackett, ...
Circulation 94 (11), 3026-3049, 1996
Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines
DA Garcia, TP Baglin, JI Weitz, MM Samama
Chest 141 (2), e24S-e43S, 2012
Idarucizumab for dabigatran reversal—full cohort analysis
CV Pollack Jr, PA Reilly, J Van Ryn, JW Eikelboom, S Glund, ...
New England Journal of Medicine 377 (5), 431-441, 2017
Accuracy of clinical assessment of deep-vein thrombosis
PS Wells, J Hirsh, DR Anderson, AWA Lensing, G Foster, C Kearon, ...
The Lancet 345 (8961), 1326-1330, 1995
The system can't perform the operation now. Try again later.
Articles 1–20